8月25日晚，Mirxes Holding Company Limited（股份代号：2629.HK）（后简称Mirxes觅瑞）正式发布了 截至2025年6月30日的中期业绩。作为一家专注于 miRNA 技术的生物科技公司，公告展现出公司在核 心产品商业化进程、财务指标优化以及研发管线推进等关键层面，均取得了显著成果，彰显出强大的增 长潜能。 收益稳健上扬，财务结构持续优化 由已公布的数据可知，Mirxes觅瑞在上半年实现收入1,050万美元，相较于2024年同期增长9.4%。这一 成绩主要归功于早期检测及精准多组学分部的卓越表现，该分部收益实现50%的增长，占公司收益比例 跃升至100%。同时，该分部毛利实现710万美元，较上年同期增长102.9%。 得益于高毛利率产品的早期检测及精准多组学分部产品销售提升及有效的成本管理，Mirxes觅瑞毛利实 现710万美元，同比增长51.1%，毛利率由49.0%提升至67.6%。 此外，非经营性因素的积极贡献，叠加精细化管理促使销售及分销开支、一般及行政费用、研发开支的 降低，诸多因素共同作用，使得期内亏损同比减少36.3%，降至2,823万美元。 今年5月23日，M ...

Core Viewpoint - Mirxes-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the FDA in the US [1] - GASTROClear has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - Guoyuan International believes that the company has significant technological, product, and market advantages in the field of miRNA-based early cancer detection, positioning it as one of the global leaders in this sector [1] - Everbright Securities International previously noted the vast market potential for global cancer screening, highlighting high industry entry barriers [1] - GASTROClear is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share (66.3%) in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]